Nanoparticle Formulations of Cisplatin for Cancer Therapy

Overview

Journal Wiley Interdiscip Rev Nanomed Nanobiotechnol

Specialty Biotechnology

Date 2016 Feb 6

PMID 26848041

Citations 54

Authors

Xiaopin Duan

Chunbai He

Stephen J Kron

Wenbin Lin

Affiliations

Soon will be listed here.

Abstract

The genotoxic agent cisplatin, used alone or in combination with radiation and/or other chemotherapeutic agents, is an important first-line chemotherapy for a broad range of cancers. The clinical utility of cisplatin is limited both by intrinsic and acquired resistance and dose-limiting normal tissue toxicity. That cisplatin shows little selectivity for tumor versus normal tissue may be a critical factor limiting its value. To overcome the low therapeutic ratio of the free drug, macromolecular, liposomal, and nanoparticle drug delivery systems have been explored toward leveraging the enhanced permeability and retention effect and promoting delivery of cisplatin to tumors. Here, we survey recent advances in nanoparticle formulations of cisplatin, focusing on agents that show promise in preclinical or clinical settings. WIREs Nanomed Nanobiotechnol 2016, 8:776-791. doi: 10.1002/wnan.1390 For further resources related to this article, please visit the WIREs website.

Citing Articles

Nanocarrier-mediated cancer therapy with cisplatin: .

Ranasinghe R, Mathai M, Alshawsh M, Zulli A Heliyon. 2025; 10(7):e28171.

PMID: 39839154 PMC: 11747978. DOI: 10.1016/j.heliyon.2024.e28171.

Nanotechnology for the Diagnosis and Treatment of Liver Cancer.

Cai Y, Wang W, Jiao Q, Hu T, Ren Y, Su X Int J Nanomedicine. 2024; 19:13805-13821.

PMID: 39735328 PMC: 11681781. DOI: 10.2147/IJN.S490661.

Precious Cargo: The Role of Polymeric Nanoparticles in the Delivery of Covalent Drugs.

Weissberger D, Stenzel M, Hunter L Molecules. 2024; 29(20).

PMID: 39459317 PMC: 11510600. DOI: 10.3390/molecules29204949.

Metal-based nanoparticle in cancer treatment: lessons learned and challenges.

Hheidari A, Mohammadi J, Ghodousi M, Mahmoodi M, Ebrahimi S, Pishbin E Front Bioeng Biotechnol. 2024; 12:1436297.

PMID: 39055339 PMC: 11269265. DOI: 10.3389/fbioe.2024.1436297.

Cisplatin-based Liposomal Nanocarriers for Drug Delivery in Lung Cancer Therapy: Recent Progress and Future Outlooks.

Mohammad-Jafari K, Naghib S, Mozafari M Curr Pharm Des. 2024; 30(36):2850-2881.

PMID: 39051580 DOI: 10.2174/0113816128304923240704113319.

References

Hamelers I, de Kroon A . Nanocapsules: a novel lipid formulation platform for platinum-based anti-cancer drugs. J Liposome Res. 2007; 17(3-4):183-9. DOI: 10.1080/08982100701530290. View

Li J, Yap S, Yoong S, Nayak T, Chandra G, Ang W . Carbon nanotube bottles for incorporation, release and enhanced cytotoxic effect of cisplatin. Carbon N Y. 2019; 50(4):1625-1634. PMC: 6522380. DOI: 10.1016/j.carbon.2011.11.043. View

Mallick A, More P, Ghosh S, Chippalkatti R, Chopade B, Lahiri M . Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells. ACS Appl Mater Interfaces. 2015; 7(14):7584-98. DOI: 10.1021/am5090226. View

Nishiyama N, Kato Y, Sugiyama Y, Kataoka K . Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm Res. 2001; 18(7):1035-41. DOI: 10.1023/a:1010908916184. View

Xiong Y, Jiang W, Shen Y, Li H, Sun C, Ouahab A . A poly(γ, L-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery. Biomaterials. 2012; 33(29):7182-93. DOI: 10.1016/j.biomaterials.2012.06.071. View

Plummer R, Wilson R, Calvert H, Boddy A, Griffin M, Sludden J . A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer. 2011; 104(4):593-8. PMC: 3049602. DOI: 10.1038/bjc.2011.6. View

Croy S, Kwon G . Polymeric micelles for drug delivery. Curr Pharm Des. 2006; 12(36):4669-84. DOI: 10.2174/138161206779026245. View

Lu C, Perez-Soler R, Piperdi B, Walsh G, Swisher S, Smythe W . Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol. 2005; 23(15):3495-501. DOI: 10.1200/JCO.2005.00.802. View

Kumari A, Yadav S, Yadav S . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2009; 75(1):1-18. DOI: 10.1016/j.colsurfb.2009.09.001. View

10.

Hirai M, Minematsu H, Hiramatsu Y, Kitagawa H, Otani T, Iwashita S . Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. Int J Pharm. 2010; 391(1-2):274-83. DOI: 10.1016/j.ijpharm.2010.02.030. View

11.

Xiao H, Song H, Yang Q, Cai H, Qi R, Yan L . A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials. 2012; 33(27):6507-19. DOI: 10.1016/j.biomaterials.2012.05.049. View

12.

Min Y, Mao C, Xu D, Wang J, Liu Y . Gold nanorods for platinum based prodrug delivery. Chem Commun (Camb). 2010; 46(44):8424-6. DOI: 10.1039/c0cc03108a. View

13.

Della Rocca J, Werner M, Kramer S, Huxford-Phillips R, Sukumar R, Cummings N . Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy. Nanomedicine. 2014; 11(1):31-8. PMC: 4280316. DOI: 10.1016/j.nano.2014.07.004. View

14.

Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T . Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005; 93(6):678-87. PMC: 2361620. DOI: 10.1038/sj.bjc.6602772. View

15.

Aryal S, Hu C, Zhang L . Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano. 2009; 4(1):251-8. PMC: 2830398. DOI: 10.1021/nn9014032. View

16.

Comenge J, Romero F, Sotelo C, Dominguez F, Puntes V . Exploring the binding of Pt drugs to gold nanoparticles for controlled passive release of cisplatin. J Control Release. 2011; 148(1):e31-2. DOI: 10.1016/j.jconrel.2010.07.041. View

17.

Lee S, OHalloran T, Nguyen S . Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J Am Chem Soc. 2010; 132(48):17130-8. PMC: 3657616. DOI: 10.1021/ja107333g. View

18.

Song H, Wang R, Xiao H, Cai H, Zhang W, Xie Z . A cross-linked polymeric micellar delivery system for cisplatin(IV) complex. Eur J Pharm Biopharm. 2012; 83(1):63-75. DOI: 10.1016/j.ejpb.2012.09.004. View

19.

Ren L, Huang X, Zhang B, Sun L, Zhang Q, Tan M . Cisplatin-loaded Au-Au2S nanoparticles for potential cancer therapy: cytotoxicity, in vitro carcinogenicity, and cellular uptake. J Biomed Mater Res A. 2007; 85(3):787-96. DOI: 10.1002/jbm.a.31608. View

20.

He C, Lu K, Liu D, Lin W . Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J Am Chem Soc. 2014; 136(14):5181-4. PMC: 4210117. DOI: 10.1021/ja4098862. View